|
|
TTD Drug ID:
DAP000475
Drug
Information |
Name | Minaprine | Synonyms | AC1L1HMV; Spectrum4_000418; D05039; M3157_SIGMA; IDI1_000063; Minaprina [INN-Spanish]; BSPBio_002909; NCGC00016795-01; KBioSS_001814; Prestwick1_000066; BPBio1_000277; Minaprinum; Spectrum5_001593; BRD-K02867583-300-05-5; CB 30038; MolPort-003-958-699; CHEBI:51038; CHEMBL278819; Cantor; DB00805; CAS-25953-17-7; SPBio_001454; 4-Methyl-3-(2-morpholinoethylamino)-6-phenylpyridazin; AR-1G3866; 4-methyl-N-(2-morpholin-4-ylethyl)-6-phenylpyridazin-3-amine; 25905-77-5; KBio2_001814; KBioGR_000716; EINECS 247-329-8; AB00053599; KBio3_002409; KBio2_004382; Spectrum2_001407; Spectrum3_001445; SPBio_002172; Cantor (TN); DivK1c_000063; Prestwick0_000066; CID4199; NINDS_000063; Minaprina; Brantur; L001202; Minaprine dihydrochloride; Prestwick3_000066; N-(4-Methyl-6-phenyl-3-pyridazinyl)-4-morpholineethanamine; Minaprinum [INN-Latin]; 25953-17-7 (di-hydrochloride); KBio2_006950; Minaprine (USAN/INN); KBio1_000063; Spectrum_001334; M3157_FLUKA; BSPBio_000251; Prestwick2_000066; minaprine; Minaprine [USAN:BAN:INN]; 4-Morpholineethanamine, N-(4-methyl-6-phenyl-3-pyridazinyl)-; ZINC19796082; 4-(2-((4-Methyl-6-phenyl-3-pyridazinyl)amino)ethyl)morpholine; AC1Q4YHU; AGR 1240; LS-92883; 3-(morpholinoethyl)amino-4-methyl-6-phenylpyridazine; NCGC00016795-02 | Indication | Depression [ICD9: 311 ICD10: F32] | Approved [1] | Structure |
Click to save drug structure in 3D MOL format
Click to save drug structure in 2D MOL format
| InChI | 1S/C17H22N4O/c1-14-13-16(15-5-3-2-4-6-15)19-20-17(14)18-7-8-21-9- 11-22-12-10-21/h2-6,13H,7-12H2,1H3,(H,18,20) | InChIKey | LDMWSLGGVTVJPG-UHFFFAOYSA-N | Canonical SMILES | CC1=CC(=NN=C1NCCN2CCOCC2)C3=CC=CC=C3 | Therapeutic Class | Antidepressive Agents | CAS Number | CAS 25905-77-5 | Formula | C17H22N4O | PubChem Compound ID | CID 4199. | PubChem Substance ID | SID 213627. | ChEBI | 51038; | SuperDrug ATC ID | N06AX07 | SuperDrug CAS ID | 025905775; | Target | 5-hydroxytryptamine 2B receptor |  | Antagonist | [2][3] | Ref 1 | Novel cholinesterase inhibitors as future effective drugs for the treatment of Alzheimer's disease. Expert Opin Investig Drugs. 2006 Jan;15(1):1-12. To Reference | Ref 2 | Mini Rev Med Chem. 2007 Nov;7(11):1108-19.Privileged structures: a useful concept for the rational design of new lead drug candidates. To Reference | Ref 3 | Protective effect of minaprine against the abnormal changes of 2-deoxyglucose uptake by rat hippocampal slices induced by hypoxia/hypoglycemia. Jpn J Pharmacol. 1992 Sep;60(1):33-8. To Reference |
Welcome
to sign our Guestbook.
If you
find any error in data or bug in web service, please kindly report it
to Dr.
Zhu.
Dr.
Chen Yuzong
Deputy Director of Center
for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore
All rights reserved.
|